Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Non-Current Debt: 2013-2025

Historic Non-Current Debt for Fortress Biotech (FBIO) over the last 13 years, with Sep 2025 value amounting to $47.8 million.

  • Fortress Biotech's Non-Current Debt fell 8.96% to $47.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.8 million, marking a year-over-year decrease of 8.96%. This contributed to the annual value of $58.0 million for FY2024, which is 4.76% down from last year.
  • Per Fortress Biotech's latest filing, its Non-Current Debt stood at $47.8 million for Q3 2025, which was down 4.50% from $50.0 million recorded in Q2 2025.
  • In the past 5 years, Fortress Biotech's Non-Current Debt ranged from a high of $91.7 million in Q4 2022 and a low of $42.6 million during Q3 2021.
  • Its 3-year average for Non-Current Debt is $57.7 million, with a median of $56.4 million in 2025.
  • Per our database at Business Quant, Fortress Biotech's Non-Current Debt skyrocketed by 114.16% in 2022 and then slumped by 49.77% in 2023.
  • Fortress Biotech's Non-Current Debt (Quarterly) stood at $42.9 million in 2021, then skyrocketed by 113.64% to $91.7 million in 2022, then slumped by 33.66% to $60.9 million in 2023, then declined by 4.76% to $58.0 million in 2024, then dropped by 8.96% to $47.8 million in 2025.
  • Its last three reported values are $47.8 million in Q3 2025, $50.0 million for Q2 2025, and $56.4 million during Q1 2025.